Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer

NCT03023722 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: anetumab ravtansine

Sponsor

Yale University

Collaborators

[object Object]